Prot #CA224047: A Randomized Double-Blind Phase 2/3 Study of Relatlimab Combined with Nivolumab versus Nivolumab in Participants with Previously Untreated Metastatic or Unrsectable Melanoma

Project: Research project

StatusActive
Effective start/end date3/21/193/21/22

Funding

  • Bristol-Myers Squibb Company (Prot #CA224047)